Cambrex to double size of Edinburgh solid form screening facility30 Jul 2019
The expanded laboratory space will allow the installation of additional instruments and reactors for larger scale crystallization studies and solid form screening capabilities.
Cambrex is expanding its solid form screening and crystallization process development facility in Edinburgh, Scotland, doubling the current footprint to 15,000 sq. ft.
The site currently has 50 employees and the expansion will add additional laboratory space to enable the recruitment of up to 40 more scientists, with the potential for further growth in the future.
Fit out is expected to begin in late August 2019 with a target completion date of the end of the year.
Cambrex’s Edinburgh site is a world-leader in providing solid form development services for drug substance and drug product. These include solid state investigations such as salt, co-crystal and polymorph screening, in addition to crystallization process development and GMP analytical services.
The expanded laboratory space will allow the installation of additional instruments and reactors for larger scale crystallization studies and solid form screening capabilities. Plans are in place for the installation of new ultra-performance liquid chromatography (UPLC) and gas chromatography instruments, as well as additional process analytical technology (PAT) tools.
“This strategic expansion, the increase in headcount and the investment in new equipment will enable us to serve more customers in the solid state screening market,” commented Mark Benger, Edinburgh Site Director, Cambrex. He added, “We have increasingly been asked by clients for additional services such as larger scale crystallization and we will now be able to provide these as well as adding greater efficiency and capacity at the Edinburgh site.”
Edinburgh became part of Cambrex’s global network of development and manufacturing facilities after the acquisition of Avista Pharma Solutions earlier this year. The facility was formerly known as Solid Form Solutions, an industry leader in solid state services, prior to the acquisition.
CPhI and AAPS partner to expand expert scientific content at CPhI North America
10 Jan 2020
CPhI and the American Association of Pharmaceutical Scientists (AAPS) today announced a partnership to expand the scientific content of activities sponsored by CPhI, including CPhI North America—the only event to bring the entire North American pharmac...Read more
Mylan recalls batches of Nizatidine capsules after nitrosamine detected in API
9 Jan 2020
The US arm of generic and specialty pharma company Mylan Pharmaceuticals has recalled three lots of its heartburn drug Nizatidine in capsule form amid fears of possible nitrosamine contamination.Read more
New HQ for developer of world's first fully automated drug discovery platform
8 Jan 2020
End-to-end robotic platform provides biotechnology companies, pharmaceutical corporations and academic centres with cost-effective and reproducible drug discovery data.Read more
Catalent completes purchase of biologics fill-finish and oral solid dose facility
7 Jan 2020
Facility provides European customers with great biologics and oral dose capabilities that can help reduce time-to-market.Read more
Boxing clever: Smart packs improving communication with patients
6 Jan 2020
Drug industry expectations of packaging are evolving with developers now seeking techs that help patients get more from their medicines.Read more
WuXi STA opens large-scale oligonucleotide manufacturing facility
6 Jan 2020
Expands company's capacity and capability for this novel modality, providing a one-stop shop from preclinical to commercial.Read more
NIH researchers discover new autoinflammatory disease
3 Jan 2020
Mutations in the RIPK1 gene responsible for CRIA syndrome.Read more
UCB to build new biotech manufacturing plant in Belgium
31 Dec 2019
Capacity to serve global late-stage development and commercial manufacturing of monoclonal antibody drug substance to support new product launches.Read more
BioAscent scientists help identify potential new treatments for cancer
30 Dec 2019
Collaboration discovers potent and selective inhibitors of enzymes associated with the development of some cancers and neurodegenerative diseases.Read more
Astellas strengthens immuno-oncology pipeline with acquisition of Xyphos Biosciences
27 Dec 2019
Acquisition adds talent and proprietary therapeutic platform to accelerate next-generation cancer immunotherapy.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation